Chronic Refractory Cough
Conditions
Brief summary
The purpose of this study is to determine the antitussive effect size and dose response of FP01 lozenges in subjects with chronic cough and to demonstrate the safety and tolerability of FP01 lozenges in subjects with chronic cough.
Interventions
DRUGFP01
DRUGplacebo
Sponsors
Avalo Therapeutics, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject must sign an Institutional Review Board approved informed consent and agree to complete required clinic visits * Subjects must be able to read and write English * Subject must exceed a cough severity threshold (VAS) during screening visit (Cough Severity VAS Score ≥ 35 mm) * Mean CSD frequency domain (Only Questions 1-3 at time of screening) score \> 3.0 * Stable chest X-ray * Forced expiratory volume 1 (FEV1) and forced vital capacity (FVC) \>70% predicted measured using spirometry * Body mass index (BMI) 18.5 - 38 * Subjects must be non-smokers or have refrained from using nicotine or nicotine containing products for at least 6 months * Female subjects should be either post-menopausal (amenorrhea for at least 12 consecutive months), surgically sterile, or women of child-bearing potential with a negative serum beta human chorionic gonadotropin pregnancy test prior to entering the study and who are using or agree to use an acceptable method of contraception as determined by the Investigator
Exclusion criteria
* Recent significant change in pulmonary status or upper respiratory tract infection (\<4 weeks of randomization) * Female subjects who are pregnant, breast feeding or sexually active without contraception. * History of chronic obstructive pulmonary disease (COPD) * History of asthma that required any significant change in treatment within 2 weeks of randomization. Subjects with asthma are eligible as long as the subject is not being treated with oral steroids but may enroll as long as no new medication to control their asthma has been prescribed within two weeks of study enrollment. * History of inhalational exposure (chemical, smoke, water, etc.) within 6 months of randomization * Chest X-ray suggestive of granulomatous disease, malignancy, pneumonia, other acute pulmonary or pleural processes * Current treatment with angiotensin converting enzyme (ACE) inhibitors * Recent myocardial infarction, or history of congestive cardiac failure * Active, concomitant disease which might limit the ability of the subject to participate in the study as determined by the Investigator (i.e., diabetes mellitus, congestive heart failure, unstable angina, etc.) * Prior or current renal disease; calculated creatinine clearance \< 30 mL/min (calculated CrCl \< 30) * History of Human Immunodeficiency Virus (HIV) or current clinically significant liver disease * Use of opioids, neuromodulators (eg., gabapentin, pregabalin) first generation antihistamines (eg., diphenhydramine, chlorpheniramine) or antidepressants for the treatment of cough, during the study. Subjects taking drugs in these classes for chronic cough at time of screening may have them discontinued at least 2 days prior to randomization. * Use of other NMDA-receptor antagonists (e.g. dextromethorphan, ketamine, amantadine) within 2 days of randomization * Use of any of the following medications which may interact with memantine: quinidine, nicotine, neuroleptics such as chlorpromazine and promethazine, amitriptyline, baclofen, warfarin and hydrochlorothiazide * Known hypersensitivity to memantine hydrochloride * Observation of oral lesion(s) or abnormal finding(s) on oral cavity examination done at study screening or Day 0 * History of oropharyngeal leukoplakia, carcinoma or parotid dysfunction * Subject has clinically significant abnormal laboratory test results at the screening visit (Subject may be enrolled by exception, as determined by the Principal Investigator and consented by Cerecor's Medical Monitor.) * Subject has had clinically significant bleeding or donated blood or plasma within 30 days of randomization * Subject has history of alcohol or drug abuse in past 2 years * Subject has a positive drug and alcohol screen. Subjects receiving benzodiazepines by prescription, who test positive for benzodiazepines at the screening visit will be allowed. * Subjects who have any disease or condition (medical or surgical) that might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, or central nervous system function; or any other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the study drug, or that would place the subject at increased risk, as determined by the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cough Count/Frequency | Day 0-1, Day 14-15; Day 28-29, Day 42-43 | Change in start-to-end difference in cough count, active vs. placebo treatment periods |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| LCQ | Days 0, 14, 28, & 42 | Start-to-end difference in Leicester Cough Questionnaire (LCQ) score, active vs. placebo treatment periods |
| VAS Score | Days 1, 14, 28, & 42 | Start-to-end difference in Visual analogue scale (VAS) score, active vs. placebo treatment periods |
| Cough Severity Diary | Days 0, 14, 28, & 42 | Start-to-end difference in CSD score, active vs. placebo treatment periods |
Countries
United States
Outcome results
None listed